Genzyme: Next-Generation Sevelamer Bound For Clinic Next Year
This article was originally published in The Pink Sheet Daily
Executive Summary
Enzyme-replacement sales strong as firm builds on renal franchise.
You may also be interested in...
Amgen's Phosphate Binder Loss May Be Genzyme's Gain
Amgen is shelving its own development of the phosphate binder AMG 223 for treatment of hyperphosphatemia in chronic kidney disease, after Phase II results disappointed
Amgen's Phosphate Binder Loss May Be Genzyme's Gain
Amgen is shelving its own development of the phosphate binder AMG 223 for treatment of hyperphosphatemia in chronic kidney disease, after Phase II results disappointed
Amgen’s Phosphate Binder Loss May Be Genzyme’s Gain
Once expected to plunder Renagel market share, AMG 223 suddenly gets left on the shelf.